| Literature DB >> 34437393 |
Patrick Romano Monteiro1,2, Samuel Cavalcante do Amaral1, Andrei Santos Siqueira2, Luciana Pereira Xavier1, Agenor Valadares Santos1.
Abstract
Cyanobacteria are microorganisms with photosynthetic mechanisms capable of colonizing several distinct environments worldwide. They can produce a vast spectrum of bioactive compounds with different properties, resulting in an improved adaptative capacity. Their richness in secondary metabolites is related to their unique and diverse metabolic apparatus, such as Non-Ribosomal Peptide Synthetases (NRPSs). One important class of peptides produced by the non-ribosomal pathway is anabaenopeptins. These cyclic hexapeptides demonstrated inhibitory activity towards phosphatases and proteases, which could be related to their toxicity and adaptiveness against zooplankters and crustaceans. Thus, this review aims to identify key features related to anabaenopeptins, including the diversity of their structure, occurrence, the biosynthetic steps for their production, ecological roles, and biotechnological applications.Entities:
Keywords: NRPS; anabaenopeptin; cyanobacteria; peptide
Mesh:
Substances:
Year: 2021 PMID: 34437393 PMCID: PMC8402340 DOI: 10.3390/toxins13080522
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1The general structure of the class of Anabaenopeptins. X corresponds to different amino acids in their respective positions represented by the superscript numbers.
Figure 2Structures of anabaenopeptins A–J [20,26,35,38,42] and T [41].
Figure 3Example of different nomenclatures to anabaenopeptin-like structures [20,23,39,46,47,48,50].
Amino acid composition of anabaenopeptin-like peptides obtained from sponges. Amino acids are considered in L-configuration unless otherwise defined. Ala: Alanine; Arg: Arginine; Ile: Isoleucine; Leu: Leucine; Lys: Lysine; MeLeu: N-methyl-Leucine; Phe: Phenylalanine; Trp: Tryptophan; Allo-Ile: Allo-Isoleucine; 2’BrTrp: 2-bromo-5-hydroxytryptophan; NMe-6’ClTrp: 6-chloro-N-methyltryptophan; 5’OHTrp: 5’-hydroxytryptophan; 6’BrTrp: 6’-bromotryptophan; 5’OH-6’Cl Trp: 6’-chloro-5’-hydroxytryptophan; 6’ClTrp: 6’-chloro-tryptophan; NMe-5OHTrp: N-methyl-5’-hydroxytryptophan; NMe-5’BrTrp: 5’-Bromo-N-methyltryptophan.
| Nomenclature | Position | Reference | ||||||
|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |||
| Konbamide | - | Leu | L-Lys | Ala | Leu | MeLeu | 2’BrTrp | [ |
| Keramide | A | Phe | L-Lys | Leu | Leu | 5’OH-6’ClTrp | Phe | [ |
| L | Phe | L-Lys | Leu | Leu | NMe-6′ClTrp | Phe | [ | |
| Paltolide | A | Arg | D-Lys | Ala | Leu | Leu | Trp | [ |
| B | Arg | D-Lys | Ala | Leu | MeLeu | 5’OHTrp | [ | |
| C | Arg | D-Lys | Ala | Leu | MeLeu | 6’BrTrp | [ | |
| Unnamed | 1 | Arg | D-Lys | Ala | Leu | MeLeu | 5’OH-6’ClTrp | [ |
| 2 | Arg | D-Lys | Ala | Leu | MeLeu | 6’ClTrp | [ | |
| 3 | Arg | D-Lys | Ala | Leu | MeLeu | Trp | [ | |
| Mozamide | A | Allo-Ile | L-Lys | D-Val | Leu | NMe-5OHTrp | Phe | [ |
| B | Allo-Ile | L-Lys | D-Ile | Leu | NMe-5OHTrp | Phe | [ | |
| Psymbamide | A | Ile | D-Lys | Leu | Leu | NMe-5’BrTrp | Phe | [ |
Figure 4Structures of anabaenopeptin-like peptides obtained from sponges [28,29,30,31,32,33].
Figure 5Examples of untypical features of anabaenopeptins from cyanobacteria [12,22,24,34,52,53].
Figure 6Example of Anabaenopeptins with unusual structures lacking one amino acid (Anabaenopeptin 679) and two amino acids (Namalide B) residues [53,55,56].
Occurrence of anabaenopeptins in different cyanobacteria genera and species.
| Strains | Anabaenopeptin | Reference |
|---|---|---|
|
| ||
| Anabaenopeptins B and D | [ | |
| Anabaenopeptins B and D | [ | |
| Anabaenopeptins B and C | [ | |
| Anabaenopeptins I and J | [ | |
| Lyngbyaureamide A and B | [ | |
| Anabaenopeptins B and F | [ | |
| Ferintoic acids A and B | [ | |
| Anabaenopeptins A, B, E/F and Oscillamide Y | [ | |
| Anabaenopeptin HU892 | [ | |
| Anabaenopeptin KT864 | [ | |
| Anabaenopeptin F and Oscillamide Y | [ | |
| Anabaenopeptins MM823, MM850, MM913 and B | [ | |
| Anabaenopeptin KB905, KB899, G, H, 908A, 915, HU892, MM913 | [ | |
| Nodulapeptins B, C, 855B, 871, 879, 897 and 915A | [ | |
| Nodulapeptins B, C, 855B, 871, 879, 897 and 915A | [ | |
| Nodulapeptins B, C, 855B, 871, 879, 897 and 915A | [ | |
| Anabaenopeptin 807 | [ | |
| Anabaenopeptin 807 | [ | |
| Anabaenopeptin 807 | [ | |
| Anabaenopeptin 807 | [ | |
| Anabaenopeptin 807 | [ | |
| Anabaenopeptin 807 | [ | |
| Anabaenopeptin 807 | [ | |
| Anabaenopeptin 807 | [ | |
| Anabaenopeptins A and C | [ | |
| Anabaenopeptins B, E and F | [ | |
| Anabaenopeptin G and H | [ | |
| Anabaenopeptin F and Oscillamide B | [ | |
| Anabaenopeptin 908A and 915 | [ | |
| Anabaenopeptin G | [ | |
| Anabaenopeptins A and B | [ | |
| Anabaenopeptins A, B, F and Oscillamide Y | [ | |
| Anabaenopeptins A, B, F and Oscillamide Y | [ | |
| Anabaenopeptins C, 822 *, B, and F | [ | |
| Anabaenopeptins A, B, F and Oscillamide Y | [ | |
| Anabaenopeptins A, B, F and Oscillamide Y | [ | |
| Anabaenopeptins A, B, F and Oscillamide Y | [ | |
|
| Anabaenopeptins A, B, F and Oscillamide Y | [ |
|
| Anabaenopeptins A, B, C, F and Oscillamide Y | [ |
|
| Anabaenopeptins B and F | [ |
|
| Anabaenopeptin A, B, and F | [ |
| Anabaenopeptins B and F | [ | |
| Anabaenopeptin F | [ | |
| Anabaenopeptins C, 822 *, B, and F | [ | |
|
| Anabaenopeptin 899 | [ |
|
| ||
| Anabaenopeptins NZ841, NZ825 and NZ857 | [ | |
| Anabaenopeptins A, B, F, 802 *, 827 *, 809 * and Oscillamide Y | [ | |
| Nodulapeptins A, B, C, 871, 821, 839, 849, 855A, 863, 865, 867, 879, 881A, 881B, 883A, 897, 899A, 915A, 931 | [ | |
| Anabaenopeptins 841 and D | [ | |
| Anabaenopeptin B and Nodulapeptins B, C, 821, 839, 855A, 855B, 871, 879, 881A, 881B, 883A, 897, 899A, 915A, 931 | [ | |
| Anabaenopeptins 841A and D | [ | |
| Nodulapeptins 883B, 899B, 901, 915B, 917, 933 | [ | |
| Nodulapeptins 883B, 899B, 901, 915B, 917, 933 | [ | |
| Nodulapeptins 883B, 899B, 901, 915B, 917, 933 | [ | |
| and Nodulapeptins A, B, C, 821, 839, 855A, 855B, 871, 879, 881A, 881B, 883A, 897, 899A, 915A, 931 | [ | |
| Anabaenopeptins 841A and D | [ | |
| Anabaenopeptins D and 841A | [ | |
| Nodulapeptins B, C, 821, 855A, 855B, 871, 879, 881A, 881B, 883A, 897, 899A, 915A and 931 | [ | |
| Nodulapeptins 883B, 899B, 901, 915B, 917 and 933 | [ | |
| Anabaenopeptins D and 841A | [ | |
| Nodulapeptins 883B, 885, 899B, 901, 915B, 917 and 933 | [ | |
| Nodulapeptins B, C, 839, 855A, 855B, 871, 879, 881A, 881B, 883A, 897, 899A, 915A, 921 and 931 | [ | |
| Nodulapeptins 883B, 885, 899B, 901, 915B, 917 and 933 | [ | |
| Nodulapeptins A, B, C, 839, 855A, 855B, 871, 879, 881A, 881B, 883A, 897, 899A, 915A, 931 | [ | |
| Anabaenopeptins J and 807 | [ | |
| Anabaenopeptins D and 841A | [ | |
| Nodulapeptins 883B, 885, 899B, 901, 915B, 917 and 933 | [ | |
| Nodulapeptins 883B, 885, 857, 899B, 901, 915B, 917 and 933 | [ | |
| Nodulapeptins 883B, 885, 857, 899B, 901, 917 and 933 | [ | |
| Nodulapeptins B, C, 921, 839, 855A, 855B, 871, 879, 881A, 881B, 883A, 897, 899A, 915A and 931 | [ | |
| Nodulapeptins 807, 823, 851, 865, 867 and 883C | [ | |
| Nodulapeptins A, B, C, 921, 823, 839, 855A, 855B, 871, 879, 881A, 881B, 883A, 897, 899A, 915A and 931 | [ | |
| Nodulapeptins 807, 823, 849, 851, 865, 867 and 883C | [ | |
| Nodulapeptins A, B, C, 839, 849, 855A, 863, 865, 867, 871, 879, 881A, 881B, 897, 899A, 915A and 933 | [ | |
|
| ||
| Anabaenopeptins A, B, and C | [ | |
| Anabaenopeptins A and B | [ | |
| Anabaenopeptin 802A | [ | |
| Anabaenopeptin 802A | [ | |
| Anabaenopeptins 788, 802A, 802B and 816 | [ | |
| Anabaenopeptins 848, 849, 862, 863, 877A, 877B, 891 and 905 | [ | |
| Anabaenopeptins 841B, 855, 857 and 871 | [ | |
| Anabaenopeptins 882 and 896 | [ | |
| Anabaenopeptins 808 *, 828, 842 *, 844 * and 858 *, | [ | |
| Anabaenopeptin SA9, SA10, SA11 and SA12 | [ | |
| Anabaenopeptins KVJ827, KVJ841, and KVJ811 | [ | |
| Schizopeptin 791 | [ | |
* Anabaenopeptin variants with non-elucidated sequence.
Figure 7The number of Anabaenopeptins variants detected and shared among strains of cyanobacteria from different environments, including environmental samples.
Figure 8Relative frequency (%) of amino acids in positions 1 and 3–6 of variants of anabaenopeptins characterized according to their environment (freshwater, marine and terrestrial). The total number of variants with elucidated sequences were 42, 47 and 29 for freshwater, marine, and terrestrial environments, respectively. Position 2 was omitted as the D-Lys residue being conservated among AP variants.
Figure 9Major factors involved in anabaenopeptin regulation in cyanobacteria.
Figure 10Anabaenopeptin cluster (apt) organization from different cyanobacteria strains. The genes aptA1, aptA2, aptA, aptB, aptC, aptD and aptE are Non-Ribosomal Peptide Synthetases (NRPSs) related to Anabaenopeptin production; hphA gene belongs to homoamino acid biosynthetic pathway and hphABCD cluster. These clusters were obtained according to their accession codes (AC) from National Center for Biotechnology Information (NCBI): Anabaena sp. 90 (AC: GU174493), Nodularia spumigena CCY9414 (AC: CP007203), Nostoc punctiforme PCC 73102 (AC: CP001037), Sphaerospermopsis torques-reginae ITEP-024 (AC: KX788858), Planktothrix agardhii NIVA-CYA 126/8 (AC: EF672686), Snowella sp. 249/25 (AC: MF741700), Microcystis aeruginosa PCC 9701 (AC: HE974200), Microcystis aeruginosa SPC777 (AC: PRJNA205171), Microcystis aeruginosa PCC 9432 (AC: HE972547). This information is available on the public database NCBI (https://www.ncbi.nlm.nih.gov/; accessed on 16 March 2021).
Figure 11Scheme of biosynthesis of anabaenopeptin B in Anabaena sp. 90 by NRPS apparatus [107,110]. A: adenylation domain; T: thiolation domain; C: condensation domain; E: epimerization domain; M: N-methylation domain; Te: thioesterase domain.
Figure 12Ecological relevance of anabaenopeptins.
Detected IC50 values of some Anabaenopeptins in nM. (TAFIa: Thrombin Activatable Fibrinolysis Inhibitor; PP1: Protein Phosphatase 1).
| Anabaenopeptin | TAFIa (nM) | Carboxipeptidase A (nM) | PP1 (nM) | References |
|---|---|---|---|---|
| Anabaenopeptin 679 | - | 6740 | - | [ |
| Anabaenopeptin 908A | 1.8 | >11,000 | - | [ |
| Anabaenopeptin 915 | 530 | 130 | - | [ |
| Anabaenopeptin A | 440 | - | 104,300 | [ |
| Anabaenopeptin B | 1.5 | >60,000; 3900 | 119,500 | [ |
| Anabaenopeptin C | 1.9 | >100,000 | - | [ |
| Anabaenopeptin E | - | >60,000 | - | [ |
| Anabaenopeptin F | 1.5 | >60,000; 1100 | 44770 | [ |
| Anabaenopeptin G | - | 2–8 | - | [ |
| Anabaenopeptin H | - | 3700–10,200 | - | [ |
| Anabaenopeptin I | - | 7 | - | [ |
| Anabaenopeptin J | - | 10 | - | [ |
| Anabaenopeptin SA1 | 2.2 | - | - | [ |
| Anabaenopeptin SA10 | 7000 | - | - | [ |
| Anabaenopeptin SA11 | 15000 | - | - | [ |
| Anabaenopeptin SA12 | 4300 | - | - | [ |
| Anabaenopeptin SA13 | 2500 | - | - | [ |
| Anabaenopeptin SA2 | 16 | - | - | [ |
| Anabaenopeptin SA3 | 2.1 | - | - | [ |
| Anabaenopeptin SA4 | 3.4 | - | - | [ |
| Anabaenopeptin SA5 | 790 | - | - | [ |
| Anabaenopeptin SA6 | 51000 | - | - | [ |
| Anabaenopeptin SA7 | 13000 | - | - | [ |
| Anabaenopeptin SA8 | 4800 | - | - | [ |
| Anabaenopeptin SA9 | 31000 | - | - | [ |
| Anabaenopeptin T | - | 3–2300 | - | [ |
| Oscillamide Y | 400 | - | 72.26 | [ |
Figure 13Interaction between (A) Anabaenopeptin B (AnaB) with Thrombin Activatable Fibrinolysis Inhibitor (TAFIa) and (B) the complex between Microcystin-LR and Protein Phosphatase 1 (PP1).